Your browser doesn't support javascript.
Somatically hypermutated antibodies isolated from SARS-CoV-2 Delta infected patients cross-neutralize heterologous variants.
Yu, Haisheng; Liu, Banghui; Zhang, Yudi; Gao, Xijie; Wang, Qian; Xiang, Haitao; Peng, Xiaofang; Xie, Caixia; Wang, Yaping; Hu, Peiyu; Shi, Jingrong; Shi, Quan; Zheng, Pingqian; Feng, Chengqian; Tang, Guofang; Liu, Xiaopan; Guo, Liliangzi; Lin, Xiumei; Li, Jiaojiao; Liu, Chuanyu; Huang, Yaling; Yang, Naibo; Chen, Qiuluan; Li, Zimu; Su, Mengzhen; Yan, Qihong; Pei, Rongjuan; Chen, Xinwen; Liu, Longqi; Hu, Fengyu; Liang, Dan; Ke, Bixia; Ke, Changwen; Li, Feng; He, Jun; Wang, Meiniang; Chen, Ling; Xiong, Xiaoli; Tang, Xiaoping.
  • Yu H; Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China. yuhaisheng@gzhmu.edu.cn.
  • Liu B; The State Key Laboratory of Respiratory Disease, CAS Key Laboratory of Regenerative Biology, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangdong Provincial Key Laboratory of Biocomputing, Center for Cell Lineage and Development, Guangzhou Institutes of Biomedicine a
  • Zhang Y; The State Key Laboratory of Respiratory Disease, CAS Key Laboratory of Regenerative Biology, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangdong Provincial Key Laboratory of Biocomputing, Center for Cell Lineage and Development, Guangzhou Institutes of Biomedicine a
  • Gao X; University of Chinese Academy of Sciences, Beijing, China.
  • Wang Q; Bioland Laboratory (Guangzhou Regenerative Medicine and Health-Guangdong Laboratory), Guangzhou, China.
  • Xiang H; State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • Peng X; BGI-Shenzhen, Shenzhen, China.
  • Xie C; China National GeneBank, BGI-Shenzhen, Shenzhen, China.
  • Wang Y; Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, China.
  • Hu P; BGI-Shenzhen, Shenzhen, China.
  • Shi J; China National GeneBank, BGI-Shenzhen, Shenzhen, China.
  • Shi Q; Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.
  • Zheng P; Bioland Laboratory (Guangzhou Regenerative Medicine and Health-Guangdong Laboratory), Guangzhou, China.
  • Feng C; Guangzhou Laboratory, Guangzhou International Bio Island, Guangzhou, China.
  • Tang G; Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.
  • Liu X; BGI-Shenzhen, Shenzhen, China.
  • Guo L; China National GeneBank, BGI-Shenzhen, Shenzhen, China.
  • Lin X; Bioland Laboratory (Guangzhou Regenerative Medicine and Health-Guangdong Laboratory), Guangzhou, China.
  • Li J; Guangzhou Laboratory, Guangzhou International Bio Island, Guangzhou, China.
  • Liu C; Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.
  • Huang Y; Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.
  • Yang N; BGI-Shenzhen, Shenzhen, China.
  • Chen Q; China National GeneBank, BGI-Shenzhen, Shenzhen, China.
  • Li Z; Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.
  • Su M; BGI-Shenzhen, Shenzhen, China.
  • Yan Q; China National GeneBank, BGI-Shenzhen, Shenzhen, China.
  • Pei R; Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.
  • Chen X; BGI-Shenzhen, Shenzhen, China.
  • Liu L; China National GeneBank, BGI-Shenzhen, Shenzhen, China.
  • Hu F; BGI-Shenzhen, Shenzhen, China.
  • Liang D; China National GeneBank, BGI-Shenzhen, Shenzhen, China.
  • Ke B; BGI-Shenzhen, Shenzhen, China.
  • Ke C; China National GeneBank, BGI-Shenzhen, Shenzhen, China.
  • Li F; Bioland Laboratory (Guangzhou Regenerative Medicine and Health-Guangdong Laboratory), Guangzhou, China.
  • He J; The State Key Laboratory of Respiratory Disease, CAS Key Laboratory of Regenerative Biology, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangdong Provincial Key Laboratory of Biocomputing, Center for Cell Lineage and Development, Guangzhou Institutes of Biomedicine a
  • Wang M; The State Key Laboratory of Respiratory Disease, CAS Key Laboratory of Regenerative Biology, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangdong Provincial Key Laboratory of Biocomputing, Center for Cell Lineage and Development, Guangzhou Institutes of Biomedicine a
  • Chen L; University of Science and Technology of China, Hefei, Anhui, China.
  • Xiong X; The State Key Laboratory of Respiratory Disease, CAS Key Laboratory of Regenerative Biology, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangdong Provincial Key Laboratory of Biocomputing, Center for Cell Lineage and Development, Guangzhou Institutes of Biomedicine a
  • Tang X; State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Nat Commun ; 14(1): 1058, 2023 Feb 24.
Article in English | MEDLINE | ID: covidwho-2288034
ABSTRACT
SARS-CoV-2 Omicron variants feature highly mutated spike proteins with extraordinary abilities in evading antibodies isolated earlier in the pandemic. Investigation of memory B cells from patients primarily with breakthrough infections with the Delta variant enables isolation of a number of neutralizing antibodies cross-reactive to heterologous variants of concern (VOCs) including Omicron variants (BA.1-BA.4). Structural studies identify altered complementarity determining region (CDR) amino acids and highly unusual heavy chain CDR2 insertions respectively in two representative cross-neutralizing antibodies-YB9-258 and YB13-292. These features are putatively introduced by somatic hypermutation and they are heavily involved in epitope recognition to broaden neutralization breadth. Previously, insertions/deletions were rarely reported for antiviral antibodies except for those induced by HIV-1 chronic infections. These data provide molecular mechanisms for cross-neutralization of heterologous SARS-CoV-2 variants by antibodies isolated from Delta variant infected patients with implications for future vaccination strategy.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2023 Document Type: Article Affiliation country: S41467-023-36761-0

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2023 Document Type: Article Affiliation country: S41467-023-36761-0